AbCellera Biologics Inc. develops antibody-based medicines as a clinical-stage biotechnology company. Its updates center on antibody discovery and development programs in endocrinology, women’s health, immunology, oncology, and other areas, including work on complex targets such as GPCRs and ion channels.
Recurring news themes include clinical disclosures for ABCL635, an antibody therapeutic targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. Company announcements also cover financial results, earnings-call materials, investor conference participation, platform and manufacturing updates, and patent licensing or litigation-resolution developments.
AbCellera (Nasdaq: ABCL) announced changes in its Board of Directors, appointing Andrew W. Lo, Ph.D., as an independent director, while John Hamer, Ph.D., resigned. Dr. Lo, known for his innovative financial engineering and machine learning in drug development, will join the Audit and Compensation Committees. CEO Carl Hansen praised Dr. Lo's expertise in connecting financial structures with biomedical innovation. Hamer, who served since 2018, was acknowledged for his valuable contributions. These changes aim to enhance AbCellera's strategic direction in antibody therapy development.
AbCellera (Nasdaq: ABCL) announced an expanded Emergency Use Authorization (EUA) from the org value="ACORN:0682203466" idsrc="xmltag.org"FDA for the combination of bamlanivimab and etesevimab for pediatric patients under 12, including neonates. The EUA permits treatment for mild to moderate COVID-19 and post-exposure prophylaxis. Data from the BLAZE-1 Phase 2/3 clinical trial indicated a median symptom resolution of 7 days. The treatment shows efficacy against the Delta variant, currently prevalent in the location value="LC/us" idsrc="xmltag.org"U.S.
AbCellera (Nasdaq: ABCL) has appointed Neil Aubuchon as the new Chief Commercial Officer, bringing over 20 years of experience from renowned biopharmaceutical firms like Amgen and Eli Lilly. His role will focus on enhancing the company's commercial strategy and optimizing partnership opportunities for antibody-based therapies.
CEO Carl Hansen expressed confidence in Aubuchon's ability to evaluate and grow their portfolio. This strategic leadership change promises to strengthen AbCellera's market position in the evolving landscape of drug development.
AbCellera (Nasdaq: ABCL) reported Q3 2021 revenue of $5.5 million, down from $9.4 million in Q3 2020, attributed to reduced milestone payments from COVID-19 treatments. The company experienced a net loss of $21.4 million or ($0.08) per share, worsening from a net loss of $2.7 million or ($0.02) per share last year. Despite these losses, AbCellera achieved significant growth in its program starts and partnerships, adding 17 new programs and bringing cumulative program starts to 69. The firm retains a strong liquidity position with $753.5 million in cash and marketable securities.
AbCellera (Nasdaq: ABCL) will participate in several upcoming virtual investor conferences, including the Credit Suisse 30th Annual Virtual Healthcare Conference on November 11 at 7:30 a.m. PT, the Stifel 2021 Virtual Healthcare Conference on November 16 at 10:20 a.m. PT, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, with a recording available on November 22. Live webcasts will be accessible via AbCellera’s Investor Relations website, allowing investors to engage with the company's strategic initiatives.
AbCellera (Nasdaq: ABCL) announced a purchase agreement with the U.S. government, facilitating the supply of 614,000 doses of bamlanivimab with etesevimab for COVID-19 treatment, worth a total of $1.29 billion. Lilly will provide at least 400,000 doses by December 31, 2021. This therapy has reportedly treated over 535,000 patients, potentially preventing more than 25,000 hospitalizations and saving over 10,000 lives. Bamlanivimab is also part of AbCellera's broader efforts to combat COVID-19.
AbCellera (Nasdaq: ABCL) will release its third quarter 2021 financial results on November 9, 2021, followed by an earnings call at 2:00 p.m. PT (5:00 p.m. ET). The live conference can be accessed through AbCellera’s Investor Relations website, where a replay will also be available. AbCellera is a technology firm that aids in the discovery and development of antibodies for drug development by collaborating with a range of pharmaceutical and biotechnology partners.
AbCellera (Nasdaq: ABCL) has partnered with Everest Medicines Limited to discover therapeutic antibodies for up to 10 selected targets, primarily in oncology. This multi-year collaboration aims to enhance Everest's drug pipeline by leveraging AbCellera’s advanced antibody discovery technology, including humanized antibodies and bispecifics. Everest will develop and commercialize the resulting antibodies, while AbCellera will receive research payments and potential royalties. This partnership seeks to accelerate the delivery of innovative therapies to patients in Asia and beyond.
AbCellera (NASDAQ: ABCL) announced a Joint Procurement Agreement with the European Commission and Eli Lilly to supply up to 220,000 doses of bamlanivimab and etesevimab for COVID-19 treatment in Europe. This agreement allows EU/EEA countries to directly purchase these treatments after national approval. The two drugs effectively neutralize the highly contagious Delta variant, responsible for over 95% of new COVID-19 cases in the region. Bamlanivimab has already treated over 535,000 patients in the U.S., potentially preventing 25,000 hospitalizations.
AbCellera (Nasdaq: ABCL) has received expanded Emergency Use Authorization (EUA) from the FDA for bamlanivimab and etesevimab to include post-exposure prophylaxis against COVID-19. This update allows use among individuals at high risk who have been exposed to the virus. The authorization is based on Phase 3 trial results indicating up to an 80% reduction in COVID-19 risk in nursing home residents. Over 535,000 patients have been treated with these antibodies since their initial authorization.